SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
11 Jun 2020
11 Jun 2020
Historique:
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
25
6
2020
Statut:
epublish
Résumé
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.
Identifiants
pubmed: 32577634
doi: 10.1101/2020.06.11.145920
pmc: PMC7301911
pii:
doi:
Types de publication
Preprint
Langues
eng
Commentaires et corrections
Type : UpdateIn
Déclaration de conflit d'intérêts
Competing Interest Declaration K.S.C., N.W., J.S.M., and B.S.G. are inventors on International Patent Application No. WO/2018/081318 entitled “Prefusion Coronavirus Spike Proteins and Their Use.” K.S.C., O.M.A., G.B.H., N.W., D.W., J.S.M, and B.S.G. are inventors on US Patent Application No. 62/972,886 entitled “2019-nCoV Vaccine”. R.S.B. filed an invention report for the SARS-CoV-2 MA virus (UNC ref. #18752).
Références
Mol Ther Nucleic Acids. 2019 Apr 15;15:1-11
pubmed: 30785039
J Virol. 2006 Oct;80(19):9896-8
pubmed: 16973594
Nature. 2016 Mar 3;531(7592):118-21
pubmed: 26935699
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24075-24083
pubmed: 31712433
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Science. 2019 Aug 2;365(6452):505-509
pubmed: 31371616
Sci Immunol. 2016 Dec 16;1(6):
pubmed: 28111638
Nat Med. 2015 Dec;21(12):1508-13
pubmed: 26552008
Front Public Health. 2020 May 28;8:216
pubmed: 32574299
Science. 2016 Oct 14;354(6309):237-240
pubmed: 27708058
Science. 2013 Nov 1;342(6158):592-8
pubmed: 24179220
J Clin Invest. 2020 Jul 1;130(7):3348-3349
pubmed: 32352406
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Virology. 2018 Apr;517:98-107
pubmed: 29277291
Cell. 2017 Mar 23;169(1):176
pubmed: 28340344
Nat Commun. 2015 Jul 28;6:7712
pubmed: 26218507
J Virol. 2011 Dec;85(23):12201-15
pubmed: 21937658
Nat Immunol. 2018 Jan;19(1):20-28
pubmed: 29199281
JAMA. 1967 Dec 18;202(12):1075-80
pubmed: 6072745
Nature. 2016 Mar 3;531(7592):114-117
pubmed: 26855426
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Nat Microbiol. 2016 Nov 28;2:16226
pubmed: 27892925
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Science. 2013 May 31;340(6136):1113-7
pubmed: 23618766
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16157-62
pubmed: 24043791
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
Am J Epidemiol. 1969 Apr;89(4):422-34
pubmed: 4305198
Annu Rev Med. 2019 Jan 27;70:91-104
pubmed: 30691364
JAMA. 2018 Apr 10;319(14):1431-1432
pubmed: 29566112